サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1696286

プラダーウィリ症候群（PWS）の世界市場（2025年～2033年）

Global Prader-Willi Syndrome Market - 2025-2033

出版日
ページ情報
英文 180 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
プラダーウィリ症候群（PWS）の世界市場（2025年～2033年）
出版日: 2025年03月25日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界のプラダーウィリ症候群（PWS）の市場規模は、2024年に6億3,356万米ドルに達し、2033年までに10億7,880万米ドルに達すると予測され、予測期間の2025年にCAGRで6.0%の成長が見込まれます。

プラダーウィリ症候群（PWS）は、代謝、内分泌、神経機能を含む体内の複数のシステムに影響を及ぼす、希少で複雑な遺伝子疾患です。PWSは一般的に乳幼児期に重度の筋緊張低下と摂食障害を呈し、全般的発達遅延につながる可能性があります。PWS患者は成長するにつれて、斜視（交差した目）や筋骨格系の異常などの特徴的な身体的特徴とともに、知的・行動的課題を経験することが多いです。

この症候群の特徴的な症状と合併症は、診断、評価、治療に包括的で集学的なアプローチを必要とします。プラダーウィリ症候群（PWS）患者の多様なニーズに対応し、全体的なウェルビーイングと生活の質の向上を目指すには、各分野の専門家のケアチームが不可欠です。

市場力学

促進要因と抑制要因

プラダーウィリ症候群（PWS）の治療における進行中の研究

プラダーウィリ症候群（PWS）の治療における進行中の研究は、新たな治療オプションを解き明かし、既存の治療法を改良することで、市場を大きく牽引すると予測されています。PWSの背景にある遺伝的・生物学的メカニズムが科学者により深く掘り下げられるにつれて、この症候群の遺伝的原因を直接標的とする遺伝子治療を含む画期的な治療法の可能性が高まっています。これは、より効果的で長期的なソリューションにつながる可能性があり、この症状の管理方法を変える可能性があります。

例えば2025年3月、FDAはプラダーウィリ症候群（PWS）患者における過食症（過度の空腹感）に対する初の治療法を承認しました。VYKAT XR（以前はDCCRとして知られていた）は現在、PWSの成人と4歳以上の小児の両方に承認されています。Soleno Therapeuticsは、VYKAT XRが米国で2025年4月に上市すると予測しています。この画期的な達成は、PWS患者に人生を変える治療法を提供する上で重要なマイルストーンであり、我々はこの旅の一部になれたことを誇りに思います。

さらに、成長ホルモン療法や、強迫性摂食や気分障害などの行動症状に対する薬物療法など、現在の治療法を強化するための研究も進められています。これらの治療法が洗練されるにつれて、より利用しやすくなり、よりよい結果が得られるようになる可能性が高いです。さらに、進行中の研究によってPWSに対する認識が高まれば、より専門的なケアや支援サービスへの需要が高まるとみられます。

このような研究から新たな治療法や進歩が生まれるにつれ、PWS治療市場は成長し、製薬企業と患者の双方に利益をもたらすと予測されます。このような進歩は患者の予後の向上につながり、標的治療に対する需要が高まるため、進行中の研究はウィリ症候群市場の拡大の重要な促進要因となっています。

限られた治療オプション

現在、PWSの治療は、成長や筋緊張を改善する成長ホルモン療法や、行動上の問題を管理するための薬物療法など、症状への対処が中心です。これらの治療法は生活の質を改善することはできますが、症候群の根本的な遺伝的原因には対処できません。このため、PWSに関連する広範な症状を完全に解決する治療法や治療法はなく、包括的ケアには大きなギャップがあります。

PWSの根底にある遺伝子異常を修正する標的治療法がないため、長期的な管理と治療の可能性が制限されています。さらに、体重、行動、ホルモンレベルの厳格な管理を含む、絶え間ない生涯にわたるケアが必要であるため、家族や医療制度に経済的医療負担を強いることになります。このように、限られた治療オプションが症状の管理における全体的な進歩を遅らせ、効果的な治療の範囲が制限されることで、プラダーウィリ症候群（PWS）市場は妨害されると予測されます。

当レポートでは、世界のプラダーウィリ症候群（PWS）市場について研究し、市場力学、地域とセグメントの分析、競合情勢、企業プロファイルなどを提供しています。

目次

第1章 市場のイントロダクションと範囲

第2章 エグゼクティブインサイトと重要事項

  • 市場のハイライトと戦略的ポイント
  • 主要動向と将来の予測
  • 抜粋：治療タイプ別
  • 抜粋：投与経路別
  • 抜粋：地域別

第3章 市場力学

  • 影響要因
    • 促進要因
      • プラダーウィリ症候群（PWS）の治療に関する進行中の研究
      • 認知度と研究資金の増加
    • 抑制要因
      • 限られた治療オプション
      • ケアの高いコスト
    • 機会
      • 遺伝子治療の進歩
    • 影響の分析

第4章 戦略的考察と産業の見通し

  • マーケットリーダーとパイオニア
    • 新興パイオニアと著名企業
    • 確立されたリーダーともっとも売れているブランド
    • マーケットリーダーと確立された製品
  • CXOの視点
  • 最新の発展とブレークスルー
  • ケーススタディ/進行中の研究
  • 規制と償還の情勢
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大に対し推奨される戦略
  • シナリオ分析：ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格動向
  • キーオピニオンリーダー

第5章 プラダーウィリ症候群（PWS）市場：治療タイプ別

  • ホルモン療法
    • 成長ホルモン（GH）療法
    • 甲状腺ホルモン補充療法
    • 性ホルモン補充療法
  • その他

第6章 プラダーウィリ症候群（PWS）市場：投与経路別

  • 経口
  • 注射

第7章 プラダーウィリ症候群（PWS）市場：地域別、市場の分析と成長機会

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他の欧州
  • ラテンアメリカ
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他のラテンアメリカ
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他のアジア太平洋
  • 中東・アフリカ

第8章 競合情勢と市場ポジショニング

  • 競合情勢の概要と主要市場企業
  • 市場シェア分析とポジショニングマトリクス
  • 戦略的パートナーシップ、合併・買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第9章 企業プロファイル

  • Pfizer Inc.
  • Novartis AG
  • Soleno Therapeutics
  • Novo Nordisk
  • Saniona
  • Rhythm Pharmaceuticals, Inc.
  • Acadia Pharmaceuticals Inc.
  • Neuren Pharmaceuticals
  • Aardvark Therapeutics, Inc.

第10章 前提条件と研究手法

第11章 付録

目次
Product Code: PH2128

The global prader-willi syndrome market reached US$ 633.56 million in 2024 and is expected to reach US$ 1,078.80 million by 2033, growing at a CAGR of 6.0% during the forecast period 2025-2033.

Prader-Willi Syndrome (PWS) is a rare and complex genetic condition that affects multiple systems in the body, including metabolic, endocrine, and neurological functions. It typically presents in infancy with severe hypotonia (low muscle tone) and feeding difficulties, which can lead to global developmental delays. As individuals with PWS grow, they often experience intellectual and behavioral challenges, alongside distinctive physical features such as strabismus (crossed eyes) and musculoskeletal abnormalities.

The syndrome's hallmark symptoms and complications require a comprehensive, multidisciplinary approach for diagnosis, assessment, and treatment. An interprofessional care team is essential for addressing the diverse needs of individuals with Prader-Willi Syndrome, aiming to enhance their overall well-being and quality of life.

Market Dynamics: Drivers & Restraints

Ongoing Research in Treating Prader-Willi Syndrome

Ongoing research in treating prader-willi syndrome (PWS) is expected to significantly drive the market by unlocking new therapeutic options and improving existing treatments. As scientists delve deeper into the genetic and biological mechanisms behind PWS, there is increasing potential for breakthrough therapies, including gene therapy, that could directly target the genetic cause of the syndrome. This could lead to more effective, long-term solutions, potentially transforming how the condition is managed. For instance,

For instance, in March 2025, the FDA approved the first treatment for hyperphagia (excessive hunger) in individuals with Prader-Willi syndrome (PWS). VYKAT XR (formerly known as DCCR) is now approved for both adults and children aged 4 years and older with PWS. Soleno Therapeutics anticipates that VYKAT XR will be available in the U.S. starting in April 2025. This groundbreaking achievement represents a significant milestone in providing life-changing therapies for individuals affected by PWS, and we are proud to be part of this journey.

Moreover, research is also focused on enhancing current treatments, such as growth hormone therapy and medications for behavioral symptoms like compulsive eating and mood disorders. As these treatments become more refined, they are likely to become more accessible and offer better results, which will increase their adoption across healthcare settings. Additionally, increased awareness of PWS due to ongoing research will drive demand for more specialized care and support services.

As new treatments and advancements emerge from this research, the market for PWS therapies is expected to grow, benefiting both pharmaceutical companies and patients. This progress will lead to better patient outcomes and a greater demand for targeted therapies, making ongoing research a key driver for the expansion of the Prader-Willi Syndrome market.

Limited Treatment Options

Currently, treatments for PWS primarily focus on addressing symptoms, such as growth hormone therapy for improving growth and muscle tone, and medications for managing behavioral issues. While these therapies can improve quality of life, they do not address the underlying genetic causes of the syndrome. This leaves a significant gap in comprehensive care, as there are no cures or treatments that fully resolve the broad range of symptoms associated with PWS.

The lack of targeted therapies to correct the genetic abnormality at the root of PWS limits the potential for long-term management and treatment. Additionally, the need for constant, lifelong care, including strict management of weight, behavior, and hormone levels, can create financial and healthcare burdens for families and health systems. Thus, the limited treatment options are expected to hinder the Prader-Willi Syndrome (PWS) market by slowing the overall progress in managing the condition and limiting the scope of effective care.

Segment Analysis

The global prader-willi syndrome market is segmented based on the treatment type, route of administration, and region.

Hormone Therapies in the treatment type segment is expected to dominate the Prader-Willi syndrome market

The hormone therapies segment is expected to dominate the treatment of Prader-Willi Syndrome (PWS) due to the critical role hormones play in managing the condition's core symptoms. One of the most significant aspects of PWS is the hormonal imbalance, particularly deficiencies in growth hormone and sex hormones.

Growth hormone therapy, in particular, has proven essential in improving growth, muscle tone, and body composition in individuals with PWS. By stimulating growth, reducing body fat, and promoting lean muscle mass, growth hormone therapy significantly enhances the quality of life for these patients.

Geographical Analysis

North America is expected to dominate the Prader-Willi syndrome market

North America is expected to dominate the Prader-Willi Syndrome (PWS) market due to several key factors, including advanced healthcare infrastructure, increased awareness, and significant investment in research and development. The United States and Canada have some of the most well-established healthcare systems in the world, providing access to cutting-edge medical care, therapies, and specialized treatments for rare diseases like prader-willi syndrome.

North America's robust healthcare research environment, with a focus on rare genetic disorders, contributes to ongoing advancements in the treatment of prader-willi syndrome. Companies and institutions in the region are at the forefront of developing innovative therapies, including potential gene therapies and new medications, which will further enhance the management of prader-willi syndrome. For instance, in June 2023, Acadia Pharmaceuticals Inc. announced the addition of a new Phase 3 development candidate to its rare disease portfolio: ACP-101 (intranasal carbetocin), aimed at treating hyperphagia (a persistent and intense feeling of hunger) in Prader-Willi syndrome (PWS). Acadia obtained the worldwide rights to develop and commercialize ACP-101 through its acquisition of Levo Therapeutics in June 2022. As a result, North America is likely to continue dominating the PWS market by leading the way in both treatment adoption and the development of novel therapies.

The growing awareness of Prader-Willi Syndrome in North America, coupled with early diagnosis and improved management strategies, drives demand for treatments such as growth hormone therapy and medications aimed at behavioral and metabolic symptoms. Additionally, the region benefits from strong advocacy and support networks for PWS patients, which leads to more families seeking appropriate care and treatment options.

Competitive Landscape

The global market players in the prader-willi syndrome market are Pfizer Inc., Novartis AG, Soleno Therapeutics, and Novo Nordisk, among others.

Key Developments

  • In April 2024, the U.S. Food and Drug Administration has awarded Breakthrough Therapy designation to Soleno Therapeutics' diazoxide choline for treating adults and children aged 4 years and older with genetically confirmed Prader-Willi syndrome who experience hyperphagia.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming pharmaceutical advancements.
  • Type Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Type delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global prader-willi syndrome market report would provide approximately 45 tables, 46 figures, and 180 pages.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Treatment Type
  • 2.4. Snippet by Route of Administration
  • 2.5. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Ongoing Research in Treating Prader-Willi Syndrome
      • 3.1.1.2. Increased Awareness and Research Funding
    • 3.1.2. Restraints
      • 3.1.2.1. Limited Treatment Options
      • 3.1.2.2. High Cost of Care
    • 3.1.3. Opportunity
      • 3.1.3.1. Advancements in Gene Therapy
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. Latin America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Force Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. Prader-Willi Syndrome Market, By Treatment Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 5.1.2. Market Attractiveness Index, By Treatment Type
  • 5.2. Hormone Therapies*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 5.2.3. Growth Hormone (GH) Therapy
    • 5.2.4. Thyroid Hormone Replacement Therapy
    • 5.2.5. Sex Hormone Replacement Therapy
  • 5.3. Others

6. Prader-Willi Syndrome Market, By Route of Administration

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 6.1.2. Market Attractiveness Index, By Route of Administration
  • 6.2. Oral*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Injectable

7. Prader-Willi Syndrome Market, By Regional Market Analysis and Growth Opportunities

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 7.1.2. Market Attractiveness Index, By Region
  • 7.2. North America
    • 7.2.1. Introduction
    • 7.2.2. Key Region-Specific Dynamics
    • 7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 7.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 7.2.5.1. U.S.
      • 7.2.5.2. Canada
  • 7.3. Europe
    • 7.3.1. Introduction
    • 7.3.2. Key Region-Specific Dynamics
    • 7.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 7.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 7.3.5.1. Germany
      • 7.3.5.2. U.K.
      • 7.3.5.3. France
      • 7.3.5.4. Spain
      • 7.3.5.5. Italy
      • 7.3.5.6. Rest of Europe
  • 7.4. Latin America
    • 7.4.1. Introduction
    • 7.4.2. Key Region-Specific Dynamics
    • 7.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 7.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 7.4.5.1. Mexico
      • 7.4.5.2. Brazil
      • 7.4.5.3. Argentina
      • 7.4.5.4. Rest of Latin America
  • 7.5. Asia-Pacific
    • 7.5.1. Introduction
    • 7.5.2. Key Region-Specific Dynamics
    • 7.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 7.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 7.5.5.1. China
      • 7.5.5.2. India
      • 7.5.5.3. Japan
      • 7.5.5.4. South Korea
      • 7.5.5.5. Rest of Asia-Pacific
  • 7.6. Middle East and Africa
    • 7.6.1. Introduction
    • 7.6.2. Key Region-Specific Dynamics
    • 7.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

8. Competitive Landscape and Market Positioning

  • 8.1. Competitive Overview and Key Market Players
  • 8.2. Market Share Analysis and Positioning Matrix
  • 8.3. Strategic Partnerships, Mergers & Acquisitions
  • 8.4. Key Developments in Product Portfolios and Innovations
  • 8.5. Company Benchmarking

9. Company Profiles

Emerging Players

  • 9.1. Pfizer Inc.*
    • 9.1.1. Company Overview
    • 9.1.2. Product Portfolio
      • 9.1.2.1. Product Description
      • 9.1.2.2. Product Key Performance Indicators (KPIs)
      • 9.1.2.3. Historic and Forecasted Product Sales
      • 9.1.2.4. Product Sales Volume
    • 9.1.3. Financial Overview
      • 9.1.3.1. Company Revenue's
      • 9.1.3.2. Geographical Revenue Shares
      • 9.1.3.3. Revenue Forecasts
    • 9.1.4. Key Developments
      • 9.1.4.1. Mergers & Acquisitions
      • 9.1.4.2. Key Product Development Activities
      • 9.1.4.3. Regulatory Approvals, etc.
    • 9.1.5. SWOT Analysis
  • 9.2. Novartis AG
  • 9.3. Soleno Therapeutics
  • 9.4. Novo Nordisk

Established Players

  • 9.5. Saniona
    • 9.5.1. Company Overview
    • 9.5.2. Product Portfolio
      • 9.5.2.1. Product Description
      • 9.5.2.2. Product Key Performance Indicators (KPIs)
      • 9.5.2.3. Historic and Forecasted Product Sales
      • 9.5.2.4. Product Sales Volume
    • 9.5.3. Financial Overview
      • 9.5.3.1. Company Revenue
      • 9.5.3.2. Geographical Revenue Shares
      • 9.5.3.3. Revenue Forecasts
    • 9.5.4. Key Developments
      • 9.5.4.1. Mergers & Acquisitions
      • 9.5.4.2. Key Product Development Activities
      • 9.5.4.3. Regulatory Approvals, etc.
    • 9.5.5. SWOT Analysis
  • 9.6. Rhythm Pharmaceuticals, Inc.
  • 9.7. Acadia Pharmaceuticals Inc.
  • 9.8. Neuren Pharmaceuticals
  • 9.9. Aardvark Therapeutics, Inc.

LIST NOT EXHAUSTIVE

10. Assumption and Research Methodology

  • 10.1. Data Collection Methods
  • 10.2. Data Triangulation
  • 10.3. Forecasting Techniques
  • 10.4. Data Verification and Validation

11. Appendix

  • 11.1. About Us and Services
  • 11.2. Contact Us